News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
651,424 Results
Type
Article (32346)
Company Profile (640)
Press Release (618438)
Multimedia
Podcasts (55)
Webinars (11)
Section
Business (198121)
Career Advice (2104)
Deals (36477)
Drug Delivery (103)
Drug Development (78132)
Employer Resources (163)
FDA (15344)
Job Trends (14630)
News (334123)
Policy (29022)
Tag
Academia (1258)
Academic (1)
Accelerated approval (5)
Adcomms (14)
Allergies (84)
Alliances (47530)
ALS (95)
Alzheimer's disease (1336)
Antibody-drug conjugate (ADC) (139)
Approvals (15334)
Artificial intelligence (246)
Autoimmune disease (28)
Automation (13)
Bankruptcy (375)
Best Places to Work (10828)
BIOSECURE Act (22)
Biosimilars (99)
Biotechnology (437)
Bladder cancer (76)
Brain cancer (25)
Breast cancer (251)
Cancer (2111)
Cardiovascular disease (167)
Career advice (1736)
Career pathing (32)
CAR-T (148)
Cell therapy (427)
Cervical cancer (17)
Clinical research (64110)
Collaboration (844)
Compensation (522)
Complete response letters (27)
COVID-19 (2185)
CRISPR (42)
C-suite (258)
Cystic fibrosis (98)
Data (2110)
Decentralized trials (2)
Denatured (3)
Depression (49)
Diabetes (252)
Diagnostics (6314)
Digital health (18)
Diversity (3)
Diversity, equity & inclusion (37)
Drug discovery (114)
Drug pricing (101)
Drug shortages (24)
Duchenne muscular dystrophy (90)
Earnings (83439)
Editorial (38)
Employer branding (24)
Employer resources (139)
Events (109713)
Executive appointments (743)
FDA (16514)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (734)
Gene editing (109)
Generative AI (24)
Gene therapy (303)
GLP-1 (722)
Government (2880)
Grass and pollen (6)
Guidances (51)
Healthcare (15868)
Huntington's disease (23)
IgA nephropathy (29)
Immunology and inflammation (128)
Indications (29)
Infectious disease (2320)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (49)
Intellectual property (97)
Interviews (424)
IPO (17213)
IRA (41)
Job creations (4235)
Job search strategy (1439)
Kidney cancer (10)
Labor market (36)
Layoffs (538)
Leadership (19)
Legal (7307)
Liver cancer (72)
Lung cancer (299)
Lymphoma (138)
Machine learning (4)
Management (58)
Manufacturing (322)
MASH (66)
Medical device (13530)
Medtech (13535)
Mergers & acquisitions (19812)
Metabolic disorders (669)
Multiple sclerosis (82)
NASH (18)
Neurodegenerative disease (102)
Neuropsychiatric disorders (31)
Neuroscience (1889)
NextGen: Class of 2025 (5957)
Non-profit (1876)
Now hiring (40)
Obesity (360)
Opinion (248)
Ovarian cancer (69)
Pain (89)
Pancreatic cancer (80)
Parkinson's disease (149)
Partnered (19)
Patents (237)
Patient recruitment (108)
Peanut (48)
People (56766)
Pharmaceutical (132)
Pharmacy benefit managers (16)
Phase I (20145)
Phase II (28600)
Phase III (21250)
Pipeline (1192)
Policy (135)
Postmarket research (1955)
Preclinical (8119)
Press Release (64)
Prostate cancer (102)
Psychedelics (35)
Radiopharmaceuticals (261)
Rare diseases (376)
Real estate (5766)
Recruiting (64)
Regulatory (20765)
Reports (35)
Research institute (1285)
Resumes & cover letters (330)
Rett syndrome (4)
RNA editing (5)
RSV (43)
Schizophrenia (76)
Series A (135)
Series B (91)
Service/supplier (26)
Sickle cell disease (51)
Special edition (16)
Spinal muscular atrophy (145)
Sponsored (21)
Startups (3889)
State (2)
Stomach cancer (13)
Supply chain (70)
Tariffs (42)
The Weekly (51)
Vaccines (649)
Venture capitalists (44)
Weight loss (244)
Women's health (24)
Worklife (19)
Date
Today (167)
Last 7 days (852)
Last 30 days (2612)
Last 365 days (33060)
2025 (10614)
2024 (35589)
2023 (40321)
2022 (50710)
2021 (54008)
2020 (50918)
2019 (41836)
2018 (31988)
2017 (32462)
2016 (30615)
2015 (36069)
2014 (28899)
2013 (23907)
2012 (25503)
2011 (25655)
2010 (23638)
Location
Africa (672)
Alabama (59)
Alaska (6)
Arizona (161)
Arkansas (11)
Asia (42102)
Australia (6730)
California (6160)
Canada (1991)
China (536)
Colorado (265)
Connecticut (279)
Delaware (140)
Europe (87995)
Florida (861)
Georgia (203)
Hawaii (1)
Idaho (55)
Illinois (457)
India (28)
Indiana (316)
Iowa (12)
Japan (159)
Kansas (99)
Kentucky (23)
Louisiana (11)
Maine (65)
Maryland (758)
Massachusetts (4747)
Michigan (233)
Minnesota (393)
Mississippi (2)
Missouri (80)
Montana (30)
Nebraska (22)
Nevada (58)
New Hampshire (66)
New Jersey (1742)
New Mexico (30)
New York (1707)
North Carolina (1056)
North Dakota (7)
Northern California (2672)
Ohio (186)
Oklahoma (10)
Oregon (40)
Pennsylvania (1338)
Puerto Rico (12)
Rhode Island (35)
South America (1062)
South Carolina (21)
South Dakota (1)
Southern California (2241)
Tennessee (82)
Texas (888)
United States (22944)
Utah (179)
Virginia (143)
Washington D.C. (57)
Washington State (569)
West Virginia (3)
Wisconsin (51)
651,424 Results for "eisai company ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake
Eisai’s new fiscal 2027 forecast for Leqembi is roughly 50% lower than its projections a year ago.
March 26, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American headquarters in Nutley, New Jersey. A company spokesperson said the pharma remains fully committed to the U.S. market.
February 28, 2025
·
1 min read
·
Angela Gabriel
Press Releases
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
December 13, 2024
·
11 min read
Press Releases
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024
·
2 min read
Regulatory
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug not cost-effective.
March 7, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Angle PLC Announces Results of Eisai Phase 2 pilot study
March 21, 2025
·
7 min read
Policy
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has accepted Eisai’s Supplemental Biologics License Application for monthly lecanemab-irmb intravenous maintenance dosing.
June 9, 2024
·
19 min read
Press Releases
UK Company, Stablepharma Ltd, enters Phase 1 Clinical Trials with world-first Fridge-Free Tetanus & Diphtheria Vaccine
April 28, 2025
·
3 min read
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
BioArctic AB announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.
April 20, 2024
·
4 min read
Alzheimer’s disease
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals
Leqembi’s sales in the U.S. continue to underwhelm, overshadowed by its growth in international markets.
February 7, 2025
·
2 min read
·
Tristan Manalac
1 of 65,143
Next
